Health News
2007-02-08
AIDS vaccine
trial shows positive results
Atlanta-based
GeoVax Labs today reported positive safety and efficacy
results for two ongoing AIDS vaccine trials. The GeoVax
Atlanta-based
GeoVax Labs today reported positive safety and efficacy
results for two ongoing AIDS vaccine trials. The GeoVax
vaccines being tested are designed to prevent the
development of AIDS caused by HIV-1 by vaccinating
individuals prior to infection.
Results show that
one tenth of a full dose is safe and stimulates a
potentially protective anti-HIV-1 immune response, indicated
by the presence of antibodies and T cells that
recognize and control viral infections.
Based on the
safety demonstrated in this trial, a full-dose human trial
of 36 volunteers started in September. The full dose of AIDS
vaccine approximates the dose size that protected 22
of 23 (96%) nonhuman primates for more than three
years against development of AIDS. (The
Advocate)
Click here to follow The Advocate on Twitter.
Page 1 of 1